All posts by CAC2

CC Community News Digest (July 19-August 1)

Assorted news from the last two weeks: CAC2 Member blog post:  “Diagnostic delays may be improved with targeted programs. The HeadSmart program, a web-based national awareness campaign in the United Kingdom decreased time to diagnosis for pediatric brain tumors by half (3). HeadSmart included partnering with parents via “safety netting.” […]

CC Community News Digest (July 5-18)

Assorted news from the last two weeks: Cures for many rare diseases might already exist. Why aren’t we using them? Patient advocacy groups have long helped researchers find participants for clinical trials and consulted with regulators on pressing needs for their constituents. But they must now play a more active, [...]

CC Community News Digest (June 29-July 5)

Assorted news from the last week: Children conceived via assisted reproductive technology (ART) were not at increased risk of developing cancer later on, according to results of a prospective study. More than a third of adolescent and young adult (AYA) cancer survivors reported being hesitant about vaccination against COVID-19 in […]

CC Community News Digest (June 8-14)

Assorted news from the last week: In a new study led by Yale Cancer Center researchers, neuromuscular dysfunction is found to be prevalent in long-term childhood cancer survivors, continues to increase post-therapy, and is associated with adverse health and socioeconomic outcomes. The findings were published in the journal Cancer, Epidemiology, [...]

CC Community News Digest (June 1-7)

Assorted news from the last week: Late Effects Surveillance System-Study Scan is an online publication that follows survivorship issues.  Click here for the latest edition, which includes several abstracts from late-effects research studies. New Research about Ewing Sarcoma: Researchers have discovered a gene, OTUD7A, that impacts the development of Ewing [...]

CC Community News Digest (May 25-31)

Assorted news from the last week: FDA issues its final guidance on the RACE Act and specifies when sponsors must conduct pediatric studies for new cancer drugs as well as when those requirements can be waived or deferred. CAC2 Supporting Organization Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical [...]

CC Community News Digest (May 10-24)

Assorted news from the last week: Thanks to a funding partnership among CAC2 Members, Spada Pediatric Sarcoma Foundation and Sam Day Foundation created theEwing Sarcoma Research Fund with a starting corpus of $250,000 within the Beat Childhood Cancer Research Consortium.  This fund will help drive genomic sequencing for kids battling Ewing [...]